Fragment-based lead discovery: challenges and opportunities

Fragment-based lead discovery has undergone remarkable changes over the last 15 years. During this time, the pharmaceutical industry has changed dramatically as well, and continued evolution of the industry is assured. These changes present many challenges but also several opportunities for executing fragment-based drug design. This article will explore some of the more significant changes in the industry and how they may affect future discovery efforts related to fragment-based initiatives.

[1]  N. Blomberg,et al.  An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. , 2007, Current topics in medicinal chemistry.

[2]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[3]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[4]  Miles Congreve,et al.  The impact of GPCR structures on pharmacology and structure‐based drug design , 2010, British journal of pharmacology.

[5]  Gregg Siegal,et al.  Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. , 2011, Methods in enzymology.

[6]  S. Hall,et al.  Chemoproteomics-driven drug discovery: addressing high attrition rates. , 2006, Drug discovery today.

[7]  Jean M. Severin,et al.  Discovery and Design of Novel HSP90 Inhibitors Using Multiple Fragment‐based Design Strategies , 2007, Chemical biology & drug design.

[8]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[9]  J. Greef,et al.  Rescuing drug discovery: in vivo systems pathology and systems pharmacology , 2005, Nature Reviews Drug Discovery.

[10]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[11]  Rob Leurs,et al.  Transforming fragments into candidates: small becomes big in medicinal chemistry. , 2009, Drug discovery today.

[12]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[13]  Roderick E. Hubbard,et al.  Structure-based drug discovery and protein targets in the CNS , 2011, Neuropharmacology.

[14]  Jan Schultz,et al.  Integration of fragment screening and library design. , 2007, Drug discovery today.

[15]  F. Sams-Dodd,et al.  Optimizing the discovery organization for innovation. , 2005, Drug discovery today.

[16]  Michael Goodman.  Market watch: Sales of biologics to show robust growth through to 2013 , 2009, Nature Reviews Drug Discovery.

[17]  S. Friend,et al.  A network view of disease and compound screening , 2009, Nature Reviews Drug Discovery.

[18]  S. Projan,et al.  Why is big Pharma getting out of antibacterial drug discovery? , 2003, Current opinion in microbiology.

[19]  Niki S C Wong,et al.  Meeting Report: Second Singapore Biologics Manufacturing Conference , 2007, Biotechnology journal.

[20]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.

[21]  P. Hajduk.  Fragment-based drug design: how big is too big? , 2006, Journal of medicinal chemistry.

[22]  P. Hajduk,et al.  Puzzling through fragment-based drug design , 2006, Nature chemical biology.

[23]  D. Erlanson.  Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.

[24]  Chris Abell,et al.  Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. , 2009, Angewandte Chemie.

[25]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.